Abstract
The recommendation for cervical screening is that it should be based on human papillomavirus (HPV) molecular testing. For all screening programs, attention to quality assurance is required to fully realize the benefits. Internationally recognized quality assurance recommendations for HPV-based screening are needed that are ideally applicable for a variety of settings, including in low- and middle-income countries. We summarize the main points of quality assurance for HPV screening, with a focus on the selection, implementation, and use of an HPV screening test, quality assurance systems (including internal quality control and external quality assessment), and staff competence. While we recognize that it might not be possible to fulfill all points in all settings, an awareness of the issues is essential.
Funder
Bill and Melinda Gates Foundation
Subject
Obstetrics and Gynecology,Oncology
Reference39 articles.
1. World Health Organization W . Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2022. Available: https://www.who.int/publications/i/item/9789240014107 [Accessed 20 July 2022].
2. World Health Organization . WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Second Edition. World Health Organization, 2021. Available: https://www.who.int/publications/i/item/9789240030824
3. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials
4. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer;Arbyn;Vaccine,2012
5. HPV Screening for Cervical Cancer in Rural India
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献